STOCK TITAN

CorMedix Inc - CRMD STOCK NEWS

Welcome to our dedicated news page for CorMedix (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on CorMedix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CorMedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CorMedix's position in the market.

Rhea-AI Summary
CorMedix Inc. announced updates related to the anticipated launch of DefenCath, a therapeutic product for the prevention and treatment of life-threatening diseases. The Center for Medicare & Medicaid Services (CMS) has determined that DefenCath will be eligible for reimbursement under the ESRD PPS, allowing CorMedix to submit an application for a Transitional Drug Add-On Payment (TDAPA) for five years of additional payment reimbursement to outpatient providers. The list price for DefenCath has been set at $249.99 per 3ml vial, with a commitment to reduce the list price if eligible for Medicare Part B reimbursement. CorMedix also received a New Technology Add-On Payment (NTAP) for inpatient reimbursement and plans to launch commercialization on April 15, 2024 for inpatient and July 1, 2024 for outpatient, contingent upon CMS approval and implementation of the TDAPA application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. (CRMD) announces commercial and operational updates related to the anticipated launch of DefenCath®. The company submitted an HCPCS application for a J-Code to CMS for DefenCath, with a commercial availability estimate of April 15, 2024 for the inpatient setting and no sooner than July 1, 2024 for the outpatient setting. Significant interest from providers has been received, with several large and medium-sized health systems committing to put DefenCath through their P&T formulary processes in 2024. CorMedix believes it has sufficient resources to fund the commercial launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) appoints Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, while Dr. Phoebe Mounts will no longer serve as the Company’s General Counsel. Ms. Zelnick Kaufman brings over two decades of legal, compliance, and operations experience in the life sciences industry, having served in leadership roles at Akorn Pharmaceuticals and Amneal Pharmaceuticals. CorMedix aims to launch DefenCath over the coming months and transition to a commercial stage entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
management
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) joins The Leapfrog Group's Partners Advisory Committee to advocate for patient safety and infection prevention. The partnership aims to advance initiatives for patient safety and well-being, shaping the organization's long-term strategic vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
partnership
-
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) announced FDA approval of DefenCath, the first FDA-approved antimicrobial catheter lock solution in the U.S. to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is expected to be available in Q1 2024. The approval was based on a Phase 3 clinical study showing up to a 71% reduction in CRBSI risk. Edward V. Hickey, III, President of the American Association of Kidney Patients, praised the approval as a meaningful moment for patients and their healthcare providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
fda approval
-
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) announced financial results for Q3 and nine months ended Sep 30, 2023, and provided updates on recent business events. Recent highlights include FDA inspections, preparations for commercial launch, and USPTO patent issuance. The company's CEO expressed satisfaction with the progress made and looks forward to potential FDA approval of DefenCath.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
earnings
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) will report its financial results for Q3 2023 on November 14, 2023. The company focuses on developing and commercializing therapeutic products for life-threatening conditions. A corporate update conference call will be held at 4:30pm Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences earnings
-
Rhea-AI Summary
CorMedix Inc. announces acceptance of abstract for presentation at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. to present at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
Rhea-AI Summary
CorMedix announces publication of Phase 3 LOCK IT-100 study results for DefenCath in CJASN
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
clinical trial
CorMedix Inc

Nasdaq:CRMD

CRMD Rankings

CRMD Stock Data

193.49M
54.13M
1.1%
34.31%
13.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley Heights

About CRMD

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.